ClinicalTrials.gg
Status unknownNCT03692663Updated Aug 1, 2022

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

An Early Phase 1 interventional study of TABP EIC and Cyclophosphamide in Metastatic Castration-resistant Prostate Cancer, sponsored by Allife Medical Science and Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Allife Medical Science and Technology Co., Ltd. · Early Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
416th of 436
9 · median 100
Started
2018
with 21 others
Phase 1
97 of 542
54 open now
Registered
80th of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 416th largest by planned enrollment of the 436 interventional ones that give a count, is one of 22 that started in 2018, is one of 97 in phase 1, and was the 80th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.

03

Conditions studied

  • Metastatic Castration-resistant Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To enter the trial, subjects had to meet all of the following eligibility criteria:

  1. diagnosed castration-resistant prostate cancer (mCRPC);
  2. Castration level of serum testosterone (\< 50 ng/dL or \< 1.7 nmol/L);
  3. Positive expression of PSMA;
  4. According to the definition of CRPC in the Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 edition), the disease still progresses after castration and meets any of the following criteria:

    A.According to the increase in PSA level, there should be 3 consecutive increases in PSA at least 1 week apart (the increase in PSA is more than 50% of the minimum value, and PSA > 2 ng/mL); B.Progression of bone disease as defined by PCWG3, defined as the presence of 2 or more new lesions on bone scan; C.CT or MRI results suggested measurable metastasis (lymph node short diameter > 15 mm was defined as lymph node metastasis as assessed by 1.1);

  5. Expected survival time ≥6 months;
  6. Toxicity of any previous treatment had recovered to ≤ grade 1 at the time of enrollment (except hair loss and hearing loss);
  7. score of patients 0-1;
  8. Patients voluntarily participated and signed the , and followed the trial treatment plan and visit plan.

Exclusion criteria

Exclusion Criteria:

Subjects who meet one of the following conditions will not be enrolled in the trial:

  1. Previous recipients of other cell therapy products, such as dendritic cells (DC), multiple cytokine-induced killer cells (CIK), T cells, natural killer cells (NK), chimeric antigen receptor T-cell immunotherapy (CAR-T), etc.;
  2. Previous treatment with any PSMA-targeted therapy;
  3. radiotherapy was administered within 4 weeks prior to the start of study treatment;
  4. Patients with a history of biological macromolecule drug allergy;
  5. Abnormal function of major organs:

    A. (ANC) \< 1.5×109/L; count (Plt) \< 100×109/L; (Hb) \< 9 g/dL; B. Liver function: (ALT) and aspartate aminotransferase (AST) ≥2.5× (≥5×ULN for liver ); C. Renal function: serum creatinine (Cr) ≥1.5×ULN; D. (PT) > 15 s, activated partial thrombin time (APTT) was prolonged or shortened by more than 10 s (normal reference value 23 s-37 s), or international normalized ratio (INR) > 1.7; E. Pulmonary function: Severe respiratory diseases (active pulmonary tuberculosis, , interstitial lung disease, etc.)

  6. Patients required systemic long-term use or had received systemic steroids (dose equivalent to prednisone >10 mg/ day, except for patients using inhaled hormones) or other agents 30 days before enrollment;
  7. A history of severe central nervous system disorders, such as stroke or epilepsy;
  8. active diseases (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis) or need long-term immunosuppressive therapy of severe autoimmune disease (screening clinic within six weeks before any immunosuppressive therapy), or by the researchers determine in 3 months will be recurrence of subjects;
  9. have had other other than prostate cancer (other than basal or squamous cell skin cancer) in the past 5 years that are currently and require intervention;
  10. Clinically significant heart disease ( class III/IV, \< 60%);
  11. Any active (viral, bacterial, fungal) infection currently being treated or any infection requiring intravenous antibiotics for 7 or more days or intervals during the past 6 weeks or any active infection requiring oral antibiotics during the past 1 week;
  12. untreated chronic active , or chronic hepatitis B virus carriers with HBV DNA≥1000 copies /mL, or active patients;
  13. Patients who have participated in other clinical trials and used study drugs within 3 months;
  14. In the opinion of the investigator, there are other factors that are not suitable for inclusion or affect the participant's participation or completion of the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    TABP EIC treatment group

    Drug: TABP EIC Experimental Interventional Therapy

    Drug: TABP EIC · Biological: Cyclophosphamide · Biological: fludarabine

Interventions

  • DrugTABP EIC

    A single dose of 0.5, 10, and 30 million TABP EIC will be iv administered at D0, D7, and D14.

  • Cyclophosphamide will be iv administered with 250 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.

  • Biologicalfludarabine

    Fludarabine will be iv administered with 25 mg/m\^2 at D-3, D-2, and D-1 before TABP EIC infusion.

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment related adverse events as assessed by CTCAE v5.0

    Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment

    Time frame: Baseline to 1 year post infusion

Secondary outcomes

  1. The pharmacokinetic analysis of TABP EIC

    Changes in the number of CD56+/ CD3-TABP EIC in peripheral blood over time

    Time frame: D0, D1, D3, D7, D8, D10, D14, D15, D17, D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion

  2. The pharmacodynamics analysis of TABP EIC

    Changes of total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) in peripheral blood

    Time frame: Baseline to infusion date, D28±1, D60±2, D120±2, D180±7, D270±7, 和 D365±7

  3. The proportion of patients with a decrease in PSA levels from baseline.

    PSA response rate

    Time frame: Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion

  4. Progression-free survival (PFS) after TABPEIC infusion

    Survival time of patients

    Time frame: Baseline to 1 year post infusion

  5. Time to clinical progression

    The time from baseline to the appearance of increased PSA levels or imaging progression.

    Time frame: Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion

07

Study locations

1 of 1 sites recruiting
  • Tianjin pepole's hosptial
    Tianjin, 300000, China
    Recruiting
    • Huaqing Wang, Doctor · Contacthuaqingw@163.com · 18622221223
    • Jian Li, Doctor · Contactlijian_2016tj@163.com · 13032231038
    • Huaqing Wang, Doctor · Principal investigator
    • Jian Li, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2018 (actual). Primary completion is estimated for Jun 2023, 54 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 54 months is above that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2018
First posted
Oct 2, 2018
StartActual
Dec 1, 2018
Primary completionEst.
Jun 2023
CompletionEst.
Jun 2024
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03692663
Lead sponsor
Allife Medical Science and Technology Co., Ltd.
Collaborators
Tianjin People's Hospital
Responsible party
Sponsor
First posted
Oct 2, 2018
Start date
Dec 1, 2018
Primary completion
Jun 2023 (estimated)
Completion
Jun 2024 (estimated)
Last update
Aug 1, 2022

Study contacts

Huaqing Wang, Doctor
Contact
huaqingw@163.com
18622221223
Jian Li, Doctor
Contact
lijian_2016tj@163.com
13032231038
Huaqing Wang, Doctor
principal investigator · Oncology of Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin
Jian Li, Doctor
principal investigator · Urinary surgeryof Tianjin people's hospital, 190 Jianyuan Road, Hongqiao District, Tianjin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion